Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
NEW YORK, Nov. 20, 2017 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will participate in two upcoming investor conferences:
- 29th Annual Piper Jaffray Healthcare Conference
Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid, will participate in a fireside chat on Wednesday, November 29, 2017 at 9:30 a.m. ET. The conference will be held at the Lotte New York Palace Hotel in New York, NY. - Evercore ISI 2017 BioPharma Catalyst/Deep Dive Conference
Yaron Werber, MD, chief business and financial officer of Ovid, will participate in a fireside chat on Thursday, November 30, 2017 at 12:50 p.m. ET. The conference will be held at the at the Boston Harbor Hotel in Boston, MA.
Live audio webcasts of the fireside chat discussions can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. Archived replays of the webcasts will be available on the company's website for two weeks following each live discussion.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies and has initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
[email protected]
